INVESTORS & MEDIA

The 5th Congress of the European Academy of Neurology (EAN)

Jun 30, 2019 at 12:30 PM CEST


Additional Information

  • Atara Biotherapeutics will present a presentation of initial ATA188 Phase 1 safety results for patients with progressive multiple sclerosis (MS) at the 5th Congress of the European Academy of Neurology (EAN), which will take place in Oslo, Norway, June 29 to July 2, 2019.
  • Details of the presentation are as follows:
    • EPO2229: Preliminary phase 1 safety of ATA188, a pre-manufactured, unrelated donor (off-the-shelf, allogeneic) Epstein-Barr virus (EBV)-targeted T-cell immunotherapy for patients with progressive multiple sclerosis (MS)
    • Poster Presentation Date and Time: Sunday, June 30, 2019, 12:30 - 1:15 p.m. CEST
    • Session Title: MS and related disorders 6
    • Location: Screen B12 in the Poster Area in the Exhibition Hall
    • Authors: Michael P. Pender1, Suzanne Hodgkinson2, Simon Broadley3, John W. Lindsey4, Zara A. Ioannides1, Blake T. Aftab5, Daniel Munson5, Kevin Rasor5, Farahnaz Forozan5, Philippe Foubert5, Laurence Gamelin5, Amy Feng5, Jonathan Willmer5
    • Affiliations: 1. Faculty of Medicine, The University of Queensland, Brisbane, Australia. 2. South Western Sydney Clinical School, University of New South Wales, Sydney, Australia. 3. School of Medicine, Griffith University, Southport, Australia. 4. Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, USA. 5. Atara Biotherapeutics, South San Francisco, USA
View Press Release
  •